Author

Zhouting Tuo

Observed names: ZHOUTING TUO, Zhou Ting Tuo, Zhou-Ting Tuo, Zhou-ting Tuo, ZhouTing Tuo

Institutions: Second Hospital of Tianjin Medical University, Tianjin Medical University

Observed institutions: Army Medical University, Anhui Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Daping Hospital, Peking University Shenzhen Hospital, Second Hospital of Tianjin Medical University, Second Affiliated Hospital of Anhui Medical University, Tianjin Medical University, Zhejiang University

ORCID: 0000-0002-9806-2562

Observed ORCID: 0000-0002-9806-2562

OpenAlex ID: A5111078251

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

2025 · Simon I Hay, Kanyin Liane Ong, et al. · The Lancet · 858

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

2025 · Mohsen Naghavi, Hmwe Hmwe Kyu, et al. · The Lancet · 561

PDF

Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023

2025 · Patrick B Mark, Lauryn K Stafford, et al. · The Lancet · 427

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

2025 · Austin E Schumacher, Peng Zheng, et al. · The Lancet · 191

Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives

2024 · Dengxiong Li, Qingxin Yu, et al. · Redox Biology · 74

Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046

2025 · De-Chao Feng, Deng-Xiong Li, et al. · Military Medical Research · 47

RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers

2022 · Zhouting Tuo, Ying Zhang, et al. · BMC Cancer · 43

PDF

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies

2025 · Jie Wang, Fanglin Shao, et al. · Research · 39

The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

2024 · Dengxiong Li, Fanglin Shao, et al. · Cell Communication and Signaling · 31

PDF

Role of SIRT1/AMPK signaling in the proliferation, migration and invasion of renal cell carcinoma cells

2021 · Xin Wang, Youlu Lu, et al. · Oncology Reports · 31

PDF

Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential

2024 · Dengxiong Li, Jie Wang, et al. · Phytomedicine · 28

Chronobiology of the Tumor Microenvironment: Implications for Therapeutic Strategies and Circadian-Based Interventions

2024 · Dengxiong Li, Qingxin Yu, et al. · Aging and Disease · 26

PDF

Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review

2024 · Zhouting Tuo, Ying Zhang, et al. · Pharmacological Research · 25

Advancements and challenges of R-loops in cancers: Biological insights and future directions

2024 · Dengxiong Li, Fanglin Shao, et al. · Cancer Letters · 23

Basic helix–loop–helix ARNT like 1 regulates the function of immune cells and participates in the development of immune-related diseases

2024 · Fanglin Shao, Zhipeng Wang, et al. · Burns & Trauma · 23

PDF

Tracing the Evolution of Sex Hormones and Receptor‐Mediated Immune Microenvironmental Differences in Prostate and Bladder Cancers: From Embryonic Development to Disease

2025 · Dengxiong Li, Zhipeng Wang, et al. · Advanced Science · 22

ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis

2023 · Yuan Lin, Ying Zhang, et al. · BMC Cancer · 22

PDF

Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives

2024 · Dengxiong Li, Ruicheng Wu, et al. · Chinese Journal of Cancer Research · 21

Unraveling links between aging, circadian rhythm and cancer: Insights from evidence-based analysis

2024 · Dechao Feng, Yuhan Xiao, et al. · Chinese Journal of Cancer Research · 20

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance

2025 · Zhipeng Wang, Jie Wang, et al. · Journal of Pharmaceutical Analysis · 19

Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis

2023 · Zhouting Tuo, Dechao Feng, et al. · Chinese Journal of Cancer Research · 18

Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation

2025 · Dilinaer Wusiman, Yu Wang, et al. · Materials Today Bio · 16

Targeting Prolyl 4-Hydroxylase Subunit Beta (P4HB) in Cancer: New Roads to Travel

2023 · Dechao Feng, Jie Wang, et al. · Aging and Disease · 14

PDF

Expanding horizons in theragnostics: from oncology to multidisciplinary applications

2025 · Ruicheng Wu, Weizhen Zhu, et al. · La radiologia medica · 12

The application of 3D printing technology in tumor radiotherapy in the era of precision medicine

2024 · Chao Jiang, Zhiwei Jiang, et al. · Applied Materials Today · 12

Works count: 79

Citation count: 2,748

H-index: 19

I10-index: 27